{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06226129",
            "orgStudyIdInfo": {
                "id": "STUDY00000969"
            },
            "organization": {
                "fullName": "University of Massachusetts, Worcester",
                "class": "OTHER"
            },
            "briefTitle": "Gadopiclenol in Contrast Enhanced MRI of the Prostate",
            "officialTitle": "Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "gadopiclenol-in-contrast-enhanced-mri-of-the-prostate"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-02",
            "studyFirstSubmitQcDate": "2024-01-17",
            "studyFirstPostDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Nicolas Bloch, MD",
                "investigatorTitle": "Director, MRI Research",
                "investigatorAffiliation": "University of Massachusetts, Worcester"
            },
            "leadSponsor": {
                "name": "University of Massachusetts, Worcester",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Guerbet",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.",
            "detailedDescription": "Gadolinium based contrast agents with higher relaxivity have been shown to improve contrast enhancement and differentiation of tissues with increased blood perfusion or with higher microvascular density (MVD), and therefore increase visibility of cancerous tissue. In this study, the objective is to demonstrate that Gadopiclenol facilitates the detection and classification of clinically significant prostate cancer, compared to T2-W (T2 weighted image) and diffusion weighted imaging (DWI), using the detailed location-specific (individual biopsy core for each annotated target) results of subsequently performed MRI-US fusion biopsies."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ],
            "keywords": [
                "MRI",
                "Prostate",
                "Contrast Agent"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Gadopiclenol",
                    "type": "EXPERIMENTAL",
                    "description": "Gadopiclenol in dose, route of administration, and indication that is FDA-approved.",
                    "interventionNames": [
                        "Drug: Gadopiclenol"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Gadopiclenol",
                    "description": "Gadopiclenol for contrast enhanced MRI",
                    "armGroupLabels": [
                        "Gadopiclenol"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Blinded Radiology Review of Enhancement of Images, Graded 1-5",
                    "description": "Single qualitative grade for contrast enhancement quality, with each exam being graded on a scale of 1-(Fail) to 5-(Excellent) contrast enhancement quality.",
                    "timeFrame": "Through Study Completion (An Average of 1 Year Post-MRI)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Quantitative Measurements of Wash-In/Wash-Out Contrast Curve",
                    "description": "The secondary outcomes will be the quantitative measurement of the wash-in/wash-out contrast curve of the individual PI-RADS lesions.",
                    "timeFrame": "Through Study Completion (An Average of 1 Year Post-MRI)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Scheduled to undergo a clinically indicated MRI of the prostate with contrast.\n* Scheduled to undergo, or likely to be scheduled to undergo, a prostate MRI-US fusion biopsy with histology results available within 6 months of their MRI.\n\nExclusion Criteria:\n\n* Prisoner\n* Have already begun therapeutic treatment for prostate cancer including surgery (TURP, prostatectomy), radiotherapy, hormone therapy or chemotherapy.\n* Patients with end stage renal failure who are on dialysis. Patients who have chronic kidney disease or acute kidney injury are contraindicated for MRI per FDA and ACR (American College of Radiologists) guidelines and would thus be excluded as well.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sara Schiller, MPH",
                    "role": "CONTACT",
                    "phone": "774-525-1517",
                    "email": "sara.schiller1@umassmed.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "B. Nicolas Bloch, MD",
                    "affiliation": "UMass Chan Medical School",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UMass Medical School",
                    "city": "Worcester",
                    "state": "Massachusetts",
                    "zip": "01655",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.26259,
                        "lon": -71.80229
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}